Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency

Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency

Abstract CAP256V2LS, a broadly neutralizing monoclonal antibody (bNAb), is being pursued as a promising drug for HIV-1 prevention. The total level of tyrosine-O-sulfation, a post-translational modification, was known to play a key role for antibody biological activity. More importantly, here wedescr...

Full description

Bibliographic Details
Main Authors: Cindy X. Cai, Nicole A. Doria-Rose, Nicole A. Schneck, Vera B. Ivleva, Brad Tippett, William R. Shadrick, Sarah O’Connell, Jonathan W. Cooper, Zachary Schneiderman, Baoshan Zhang, Daniel B. Gowetski, Daniel Blackstock, Jacob Demirji, Bob C. Lin, Jason Gorman, Tracy Liu, Yile Li, Adrian B. McDermott, Peter D. Kwong, Kevin Carlton, Jason G. Gall, Q. Paula Lei
Format: Article
Language:English
Published: Nature Portfolio 2022-05-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-12423-x

Internet

https://doi.org/10.1038/s41598-022-12423-x

Similar Items